Performance of 18F-fluoro-ethyl-tyrosine ( 18F-FET) PET for the differential diagnosis of primary brain tumor: A systematic review and metaanalysis

Journal of Nuclear Medicine

Volumn 53, Issue 2, 2012, Pages 207-214

  Dunet, Vincent ^a   Rossier, Christine ^a   Buck, Alfred ^b   Stupp, Roger ^a   Prior, John O ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

18F fluoro ethyl tyrosine; Brain tumor; Glioma; Metaanalysis; PET

Indexed keywords

FLUORO ETHYL TYROSINE F 18; TRACER; UNCLASSIFIED DRUG; (18F)FLUOROETHYLTYROSINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; TYROSINE;

ARTICLE; BRAIN SURGERY; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DRUG TUMOR LEVEL; HISTOPATHOLOGY; HUMAN; META ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; ANIMAL; GLIOMA; METHODOLOGY; QUALITY CONTROL; REVIEW; SCINTISCANNING;

ANIMALS; BRAIN NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; GLIOMA; HUMANS; POSITRON-EMISSION TOMOGRAPHY; QUALITY CONTROL; TYROSINE;

EID: 84856802355     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.096859     Document Type: Article

References (40)

1. Central Brain Tumor Registry of the United States (CBTRUS). CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2007. Hindale, IL: CBTRUS. Available at: http://www.cbtrus.org/2011-NPCR-SEER/WEB-0407-Report-3-3-2001.pdf. Accessed January 9, 2012.
2. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97-109. (Pubitemid 47103521)
3. la Fougère C, Suchorska B, Bartenstein P, Kreth FW, Tonn JC. Molecular imaging of gliomas with PET: opportunities and limitations. Neuro-oncol. 2011;13:806-819.
4. Heiss P, Mayer S, Herz M, Wester HJ, Schwaiger M, Senekowitsch- Schmidtke R. Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-L-tyrosine in vitro and in vivo. J Nucl Med. 1999;40:1367-1373. (Pubitemid 29385647)
5. 18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med. 1999;40:205-212.
6. 11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med. 2000;27:542-549.
7. Pöpperl G, Kreth FW, Mehrkens JH, et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging. 2007;34:1933-1942. (Pubitemid 350212135)
8. 18FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro-oncol. 2011;13:307-316.
9. 18F-FDG in acute cerebral radiation injury in the rat: implications for separation of radiation necrosis from tumor recurrence. J Nucl Med. 2004;45:1931-1938.
10. 18f]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2011;80:176-184.
11. Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD Initiative. Radiology. 2003;226:24-28. (Pubitemid 36163903)
12. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25.
13. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634. (Pubitemid 27387172)
14. 18F-FET PET differentiation of ring-enhancing brain lesions. J Nucl Med. 2006;47:776-782.
15. 18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. J Nucl Med. 2007;48:519-527.
16. 18F-FDG PET in brain tumors. Nucl Med Biol. 2009;36:779-787.
17. 123I-iodo-alpha- methyl-L-tyrosine SPECT in brain tumors. J Nucl Med. 2004;45:374-381.
18. Pichler R, Dunzinger A, Wurm G, et al. Is there a place for FET PET in the initial evaluation of brain lesions with unknown significance? Eur J Nucl Med Mol Imaging. 2010;37:1521-1528.
19. 18F] fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl Med Mol Imaging. 2005;32:422-429.
20. 18F]fluoroethyl) -L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain. 2005;128:678-687.
21. 18F-FET PET and 5-ALA fluorescence in cerebral gliomas. Eur J Nucl Med Mol Imaging. 2011;38:731-741.
22. 18F] fluoroethyl-L-tyrosine and magnetic resonance spectroscopy. J Neurosurg. 2005;102:318-327.
23. Stockhammer F, Plotkin M, Amthauer H, van Landeghem FK, Woiciechowsky C. Correlation of F-18-fluoro-ethyl-tyrosin uptake with vascular and cell density in non-contrast-enhancing gliomas. J Neurooncol. 2008;88:205-210.
24. 18F]-fluoroethyl)-L-tyrosine in the diagnosis of glioblastoma. Arch Neurol. 2010;67:370-372.
25. Plotkin M, Blechschmidt C, Auf G, et al. Comparison of F-18 FET-PET with F-18 FDG-PET for biopsy planning of non-contrast-enhancing gliomas. Eur Radiol. 2010;20:2496-2502.
26. 18F-FLT for differentiation between tumor and inflammation in rats. Nucl Med Biol. 2009;36:681-686.
27. 18F-FET uptake. Contrast Media Mol Imaging. 2006;1:212-220.
28. Chang CH, Wang HE, Wu SY, et al. Comparative evaluation of FET and FDG for differentiating lung carcinoma from inflammation in mice. Anticancer Res. 2006;26:917-925.
29. 3H-deoxyglucose in brain abscesses. J Nucl Med. 2007;48:2056-2062.
30. 18F]fluoroethyl)-L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging. 2004;31:1464-1470.
31. Möller-Hartmann W, Herminghaus S, Krings T, et al. Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology. 2002;44:371-381. (Pubitemid 36097186)
32. 18F-fluoroethyl)-L- tyrosine PET and proton magnetic resonance spectroscopic imaging. J Nucl Med. 2008;49:721-729.
33. Rosenschöld PM, Engelholm S, Ohlhues L, Law I, Vogelius I, Engelholm SA. Photon and proton therapy planning comparison for malignant glioma based on CT, FDG-PET, DTI-MRI and fiber tracking. Acta Oncol. 2011;50:777-783.
34. Herzog H, Langen KJ, Weirich C, et al. High resolution BrainPET combined with simultaneous MRI. Nuklearmedizin. 2011;50:74-82.
35. 18F] Fluoroethyltyrosine: positron emission tomography-guided radiotherapy for high-grade glioma. Radiat Oncol. 2008;3:44.
36. Niyazi M, Geisler J, Siefert A, et al. FET-PET for malignant glioma treatment planning. Radiother Oncol. 2011;99:44-48.
37. 18F]fluoroethyl-tyrosine-positron emission tomography-guided radiotherapy for high-grade glioma: a prospective study. Radiother Oncol. 2009;93:586-592.
38. 18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging. 2005;32:1018-1025.
39. Vander Borght T, Asenbaum S, Bartenstein P, et al. EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues. Eur J Nucl Med Mol Imaging. 2006;33:1374-1380. (Pubitemid 44630797)
40. Langen KJ, Bartenstein P, Boecker H, et al. German guidelines for brain tumour imaging by PET and SPECT using labelled amino acids [in German]. Nuklearmedizin. 2011;50:167-173.